Welcome to
|
|
Revolutionizing the way viruses and bacteria are detected and diagnosed
|
|
MISSION
|
|
|
Guanine's mission is to contain pandemics by decentralizng pathogen testing with handheld testing instruments and rapid, simple, inexpensive and accurate tests. This will empower companies, individuals and government agencies to test whoever and whenever they want to rapidly identify viruses and bacteria while the infections are easier to be contained. With the use of AI tools individuals can make better-informed decisions such as urgently seeing a doctor at the early stage of infections when virulent pathogens are more easily treated and at a lower cost.
|
|
TECHNOLOGY
|
|
|
Guanine has developed a handheld electronic sensor and automated test cartridge that can allow businesses and consumers to detect specific viruses and bacteria with PCR accuracy in minutes at 25-50% of the cost of lab tests. Here’s how:
|
|
|
BEYOND COVID-19
The world beyond COVID-19
"COVID-19 has shown the inability of the centralized lab testing infrastructure to prevent a pandemic from devastating businesses and disrupting human lives. We need a better approach before the next pandemic."
Neil Gordon Founder and CEO, Guanine Inc. |
|
ABOUT
Our platform evolved from the convergence of nanotech, biotech, and infotech
Guanine's founder Neil Gordon was one the first business consultants in the nanotechnology sector and worked with many of the nanotechnology pioneers through his boutique consulting practice, the NanoBusiness Alliance, and the NASA-led CANEUS consortium for micro and nano technologies in the aerospace and industries. Guanine’s predecessor company was spun out of NASA’s Ames Research Center and adapted NASA’s carbon nanotube sensor to detect guanine oxidation signals from bacterial and viral RNA. Neil and his team re-engineered the NASA sensor and produced guanine oxidation from synthetic DNA comprising guanine nucleotides. When a string of nucleotides was fabricated into a quadruplex by coiling guanine molecules around sodium cations the structure produced a stronger electrical signal from 8-oxoguanine that detected lower concentrations of targets. Guanine had integrated the electronic sensor signals with artificial intelligence tools to diagnose infections from test results and symptoms.
TEAM
Neil Gordon B.Eng, MBA
President & CEO email LinkedIn Neil is a business executive specializing in managing advanced technology products and ventures. He was one of the one of first business consultants in nanotechnology. He headed commercialization for the NASA-led CANEUS and spun out a company from NASA’s Ames Research Center to commercialize NASA’s carbon nanotube sensor. He co-developed a testing instrument for detecting RNA from bacteria and viruses. He subsequently invented and patented the quadruplex detection tag, the electronic sensor, and AI diagnosis platform. |
Garry Palmateer M.Sc.
Vice President, Assays Garry is a microbiologist with over 40 years experience in detecting bacteria and viruses. Garry previously operated pathogen testing labs in the private sector and for the Ontario Government. He oversaw remediation of the Walkerton E.coli outbreak. Garry co-developed the pathogen sensor and inline testing instrument at Guanine's predecessor NASA spin-off company. He developed assay protocols for various pathogens including a rapid test for carbapenem resistance using the electronic sensor. |
Raj Bawa PhD
VP and Chief IP Officer Raj is a microbiologist and a pioneer in nanomedicine with over 100 publications. He is also a patent agent and formerly worked at the USPTO. Raj is involved in strategic projects, and intellectual property activities. |
Ara Altounian B.Eng, MBA
Vice President, Operations Ara is an engineer with diverse experience in engineering, retail, software design and instruments. His career spans many aspects of management, operations, and administration. |
CONTACT
|
|
